FLX-925 (AMG-925) trihydrate is primarily investigated for its potential in cancer therapy, particularly targeting specific kinases involved in tumor growth and proliferation. It is studied for its ability to inhibit FLT3 and CDK4/6 kinases, which are critical in the development of certain types of cancers, such as acute myeloid leukemia (AML) and breast cancer. By blocking these kinases, it aims to disrupt cancer cell cycle progression and induce apoptosis. Research focuses on its efficacy in preclinical models, exploring its potential as a targeted treatment option for patients with kinase-driven malignancies.